What is Rize Oncology?
Rize Oncology is a biotechnology firm focused on developing STS-201, a therapeutic agent targeting soft tissue sarcomas. These rare, diverse, and often rapidly fatal tumors represent a significant unmet medical need, positioning Rize Oncology at the forefront of advanced cancer therapy research. The company's dedication to addressing such critical conditions highlights its role in pioneering new avenues for patient care and treatment efficacy.
How much funding has Rize Oncology raised?
Rize Oncology has raised a total of $4.1M across 2 funding rounds:
Stock Offering
$3.6M
Share Placement
$500K
Stock Issuance/Offering (2022): $3.6M, investors not publicly disclosed
Share Placement (2025): $500K, investors not publicly disclosed
What's next for Rize Oncology?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for Rize Oncology. This backing is expected to accelerate the development and potential commercialization of STS-201, enabling the company to advance its clinical trials and expand its research capabilities. The strategic nature of this financing suggests a focus on achieving key milestones and solidifying its market position in the competitive oncology landscape.
See full Rize Oncology company page
